Literature DB >> 34757835

Predicting axillary response to neoadjuvant chemotherapy: the role of diffusion weighted imaging.

Lucia Graña-López1,2, Tania Pérez-Ramos1, Fiz Andrés Maciñeira1, Ángeles Villares1,2, Manuel Vázquez-Caruncho1,2.   

Abstract

OBJECTIVE: The aim of this study is to investigate whether the primary tumour response to neoadjuvant chemotherapy (NAC), based on the increase in the ADC-values (apparent diffusion coefficient) within the breast lesion, could help to predict axillary complete response.
METHODS: We retrospectively included 74 patients who were treated with NAC followed by surgery at Lucus Augusti Hospital between January 2015 and September 2020. Simple logistic regression was used to evaluate the factors associated with axillary pathological complete response, including the changes in breast tumour ADC-values due to the treatment.
RESULTS: Axillary complete response was correlated with negative oestrogen receptor status, Her2 positivity and response of primary tumour. It was achieved in 31% of the patients. In addition, the increase in the tumour ADC-values with NAC was higher for responders. Among the tumours that demonstrated an increase in ADC-value >0.92 ×10-3 mm2/s, 42.8% (15/35) showed axillary complete response. Eight (20.5%) breast cancers with an increase in ADC below the cut-off value were found to have no metastatic nodes after treatment (p = 0.038).
CONCLUSION: Our results suggest that the performance of models predicting axillary response to NAC can be improved by adding the tumour response determined also using diffusion-weighted imaging. ADVANCES IN KNOWLEDGE: For the fist time, we investigate the relation between tumour response to NAC, assessed using diffusion-weighted imaging, and axillary pathologic complete response.

Entities:  

Mesh:

Year:  2021        PMID: 34757835      PMCID: PMC8822565          DOI: 10.1259/bjr.20210511

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  14 in total

1.  Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

Authors:  Jennifer F De Los Santos; Alan Cantor; Keith D Amos; Andres Forero; Mehra Golshan; Janet K Horton; Clifford A Hudis; Nola M Hylton; Kandace McGuire; Funda Meric-Bernstam; Ingrid M Meszoely; Rita Nanda; E Shelley Hwang
Journal:  Cancer       Date:  2013-02-21       Impact factor: 6.860

Review 2.  Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review.

Authors:  R J Schipper; M Moossdorff; R G H Beets-Tan; M L Smidt; M B I Lobbes
Journal:  Eur J Radiol       Date:  2014-10-13       Impact factor: 3.528

3.  Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.

Authors:  Rihyeon Kim; Jung Min Chang; Han-Byoel Lee; Su Hyun Lee; Soo-Yeon Kim; Eun Sil Kim; Nariya Cho; Woo Kyung Moon
Journal:  Radiology       Date:  2019-08-13       Impact factor: 11.105

4.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

Authors:  Jean-Francois Boileau; Brigitte Poirier; Mark Basik; Claire M B Holloway; Louis Gaboury; Lucas Sideris; Sarkis Meterissian; Angel Arnaout; Muriel Brackstone; David R McCready; Stephen E Karp; Isabelle Trop; Andre Lisbona; Frances C Wright; Rami J Younan; Louise Provencher; Erica Patocskai; Atilla Omeroglu; Andre Robidoux
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

Review 5.  Diffusion weighted MR imaging of the breast.

Authors:  Ahmed Abdel Khalek Abdel Razek; Gada Gaballa; Adel Denewer; Ismail Tawakol
Journal:  Acad Radiol       Date:  2009-12-11       Impact factor: 3.173

6.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

Authors:  Anwar R Padhani; Guoying Liu; Dow Mu Koh; Thomas L Chenevert; Harriet C Thoeny; Taro Takahara; Andrew Dzik-Jurasz; Brian D Ross; Marc Van Cauteren; David Collins; Dima A Hammoud; Gordon J S Rustin; Bachir Taouli; Peter L Choyke
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

7.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Authors:  Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

8.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Authors:  Thorsten Kuehn; Ingo Bauerfeind; Tanja Fehm; Barbara Fleige; Maik Hausschild; Gisela Helms; Annette Lebeau; Cornelia Liedtke; Gunter von Minckwitz; Valentina Nekljudova; Sabine Schmatloch; Peter Schrenk; Annette Staebler; Michael Untch
Journal:  Lancet Oncol       Date:  2013-05-15       Impact factor: 41.316

9.  Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.

Authors:  Judy C Boughey; Linda M McCall; Karla V Ballman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa Flippo-Morton; Kelly K Hunt
Journal:  Ann Surg       Date:  2014-10       Impact factor: 12.969

10.  Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group.

Authors:  Pascal Baltzer; Ritse M Mann; Mami Iima; Eric E Sigmund; Paola Clauser; Fiona J Gilbert; Laura Martincich; Savannah C Partridge; Andrew Patterson; Katja Pinker; Fabienne Thibault; Julia Camps-Herrero; Denis Le Bihan
Journal:  Eur Radiol       Date:  2019-11-30       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.